Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) tablets is used for the treatment of patients with mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia.

VOSEVI is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, velpatasvir, an HCV NS5A inhibitor, and voxilaprevir, an HCV NS3/4A protease inhibitor, and is indicated for the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have (1, 2.2, 14): • genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. • genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. o Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor.

Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) tablets suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) tablets brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the medicine and its cost price in India.

The order for Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) tablets will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Sofosbuvir/velpatasvir/voxilaprevir (trade name Vosevi) is a combination drug for the treatment of hepatitis C. It combines three drugs that each act by a different mechanism of action against the hepatitis C virus: sofosbuvir, velpatasvir, and voxilaprevir.

VOSEVI® (sofosbuvir, velpatasvir, and voxilaprevir) tablets, for oral use Initial U.S. Approval: 2017

Generic Name: sofosbuvir, velpatasvir, and voxilaprevir

VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) tablets

Vosevi, for oral use is available.

Get In Touch

VOSEVI (sofosbuvir/velpatasvir) suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand VOSEVI (sofosbuvir/velpatasvir) on prescription and Import License in Patient's Name only.

For overseas patients, VOSEVI (sofosbuvir/velpatasvir) can be made available in Send your enquiry to find VOSEVI (sofosbuvir/velpatasvir) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for VOSEVI (sofosbuvir/velpatasvir).

What are the best hepatitis C drugs? For More Details

FDA approves Vosevi for Hepatitis C. For More Details